Lp-PLA2-IN-3

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Lp-PLA2-IN-3 是一种有效的、口服的脂蛋白相关磷脂酶 A2 (Lp-PLA2) 抑制剂，对重组人 Lp-PLA2 (Lp-PLA2) 的IC50 为14 nM。

Lp-PLA2-IN-3 is a potent and orally bioavailable lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor, with an IC50 of 14 nM for recombinant human Lp-PLA2 (rhLpPLA2).

——

Lp-PLA2-IN-3 (3 mg/kg; p.o.) treatment shows the Cmax, AUC0-24h, t1/2 and F were 0.27 μg/mL, 3.4 μg h/mL, 7.7 hours and 35.5%, respectively.Lp-PLA2-IN-3 (1 mg/kg; i.v.) treatment shows the CL, Vss, and t1/2 were 3.1mL/min/kg, 0.3 L/kg, 4 hours, respectively.Animal Model:Male Sprague?Dawley (SD) rats (180-220 g)Dosage:3 mg/kg Administration:p.o. (Pharmacokinetic Analysis)Result:The Cmax, AUC0-24h, t1/2 and F were 0.27 μg/mL, 6.2 μg h/mL, 7.7 hours and 35.5%, respectively.

——

Metabolic Enzyme/Protease

Phospholipase

Phospholipase

——

——

2196245-16-4

467.85

C20H13ClF3N3O3S

>98% (HPLC)

In Vitro:?DMSO 中的溶解度 : ≥ 250 mg/mL (534.36 mM )

Nc1ccc(cc1)S(=O)(=O)Nc1ccc(Oc2ccc(Cl)c(c2)C(F)(F)F)c(c1)C#N

——

(-20℃)

With Ice Pack

≥ 2 years